{"id":446526,"date":"2021-03-01T02:03:08","date_gmt":"2021-03-01T07:03:08","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=446526"},"modified":"2021-03-01T02:03:08","modified_gmt":"2021-03-01T07:03:08","slug":"verona-pharma-to-present-at-h-c-wainwright-global-life-sciences-virtual-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-present-at-h-c-wainwright-global-life-sciences-virtual-conference\/","title":{"rendered":"Verona Pharma to Present at H.C. Wainwright Global Life Sciences Virtual Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">LONDON and RALEIGH, N.C., March  01, 2021  (GLOBE NEWSWIRE) &#8212; Verona Pharma plc (Nasdaq: VRNA) (\u201cVerona Pharma\u201d), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Chief Executive Officer and President, will present a company overview at the H.C. Wainwright Global Life Sciences Conference. The presentation will be available on-demand starting at 7:00 AM ET on Tuesday, March 9, 2021.<\/p>\n<p>A webcast of the event will be available for 90 days on the Events and Presentations link on the Investors page of the Company\u2019s website,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=a9lq1Ls0ouI-Zn4vSFVMTfd7UpGjt3ALwgCaqkhChcgbdUlQNwGGlRP5A2o_amjEvKBn0qPo99yROOzlpCtFZqbzkqbZ0XO45BD67JdWt3M=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.veronapharma.com<\/a>.<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:50%;width:50%;min-width:50%;vertical-align: middle\">\u00a0<\/td>\n<td style=\"max-width:50%;width:50%;min-width:50%\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <strong>Verona Pharma plc<\/strong>\n          <\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">US Tel: +1-833-417-0262<br \/>UK Tel: +44 (0)20 3283 4200<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Victoria Stewart, Director of Communications<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <a href=\"mailto:info@veronapharma.com\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">info@veronapharma.com<\/a>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <strong>Argot Partners<\/strong><br \/>\n            <br \/>(US Investor Enquiries)<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Tel: +1-212-600-1902<br \/><a href=\"mailto:verona@argotpartners.com\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">verona@argotpartners.com<\/a><\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Kimberly Minarovich \/ Michael Barron<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <strong>Optimum Strategic Communications<\/strong><br \/>\n            <br \/>(International Media and European Investor Enquiries)<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Tel: +44 (0)203 950 9144<br \/><a href=\"mailto:verona@optimumcomms.com\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">verona@optimumcomms.com<\/a><\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Mary Clark \/ Eva Haas \/ Shabnam Bashir<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<\/table>\n<p>\n        <strong>About Verona Pharma<\/strong>\n      <\/p>\n<p align=\"justify\">Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharma\u2019s product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE (\u201cEnsifentrine as a Novel inHAled Nebulized COPD thErapy\u201d) for COPD maintenance treatment. Two additional formulations of ensifentrine are currently in Phase 2 development for the treatment of COPD: dry powder inhaler (\u201cDPI\u201d) and pressurized metered-dose inhaler (\u201cpMDI\u201d). Ensifentrine is being evaluated in a pilot clinical study in patients hospitalized with COVID-19 and has potential applications in cystic fibrosis, asthma and other respiratory diseases. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=a9lq1Ls0ouI-Zn4vSFVMTXZ3dqNNTDWBK5GmK9QbEdz1_ynUSKsRLCTuTD7iGRsldfRrhccIP0900RJ5Pljc-3XEZ57BcDrQGO1dmpeWhQs=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.veronapharma.com<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains forward-looking statements. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. These forward-looking statements are based on management&#8217;s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from our expectations expressed or implied by the forward-looking statements. Any such forward-looking statements represent management&#8217;s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.<\/p>\n<p>\u00a0<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE2MDk1MCMzOTk4NzI0IzIwODQzNjA=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/cd1e6edb-a709-4522-b6f6-18924f97009a\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>LONDON and RALEIGH, N.C., March 01, 2021 (GLOBE NEWSWIRE) &#8212; Verona Pharma plc (Nasdaq: VRNA) (\u201cVerona Pharma\u201d), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Chief Executive Officer and President, will present a company overview at the H.C. Wainwright Global Life Sciences Conference. The presentation will be available on-demand starting at 7:00 AM ET on Tuesday, March 9, 2021. A webcast of the event will be available for 90 days on the Events and Presentations link on the Investors page of the Company\u2019s website,\u00a0www.veronapharma.com. \u00a0 \u00a0 Verona Pharma plc US Tel: +1-833-417-0262UK Tel: +44 (0)20 3283 4200 Victoria Stewart, Director of Communications info@veronapharma.com \u00a0 \u00a0 Argot Partners (US Investor Enquiries) Tel: +1-212-600-1902verona@argotpartners.com Kimberly Minarovich \/ Michael &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-present-at-h-c-wainwright-global-life-sciences-virtual-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Verona Pharma to Present at H.C. Wainwright Global Life Sciences Virtual Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-446526","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Verona Pharma to Present at H.C. Wainwright Global Life Sciences Virtual Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-present-at-h-c-wainwright-global-life-sciences-virtual-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Verona Pharma to Present at H.C. Wainwright Global Life Sciences Virtual Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"LONDON and RALEIGH, N.C., March 01, 2021 (GLOBE NEWSWIRE) &#8212; Verona Pharma plc (Nasdaq: VRNA) (\u201cVerona Pharma\u201d), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Chief Executive Officer and President, will present a company overview at the H.C. Wainwright Global Life Sciences Conference. The presentation will be available on-demand starting at 7:00 AM ET on Tuesday, March 9, 2021. A webcast of the event will be available for 90 days on the Events and Presentations link on the Investors page of the Company\u2019s website,\u00a0www.veronapharma.com. \u00a0 \u00a0 Verona Pharma plc US Tel: +1-833-417-0262UK Tel: +44 (0)20 3283 4200 Victoria Stewart, Director of Communications info@veronapharma.com \u00a0 \u00a0 Argot Partners (US Investor Enquiries) Tel: +1-212-600-1902verona@argotpartners.com Kimberly Minarovich \/ Michael &hellip; Continue reading &quot;Verona Pharma to Present at H.C. Wainwright Global Life Sciences Virtual Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-present-at-h-c-wainwright-global-life-sciences-virtual-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-01T07:03:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE2MDk1MCMzOTk4NzI0IzIwODQzNjA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verona-pharma-to-present-at-h-c-wainwright-global-life-sciences-virtual-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verona-pharma-to-present-at-h-c-wainwright-global-life-sciences-virtual-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Verona Pharma to Present at H.C. Wainwright Global Life Sciences Virtual Conference\",\"datePublished\":\"2021-03-01T07:03:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verona-pharma-to-present-at-h-c-wainwright-global-life-sciences-virtual-conference\\\/\"},\"wordCount\":447,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verona-pharma-to-present-at-h-c-wainwright-global-life-sciences-virtual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE2MDk1MCMzOTk4NzI0IzIwODQzNjA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verona-pharma-to-present-at-h-c-wainwright-global-life-sciences-virtual-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verona-pharma-to-present-at-h-c-wainwright-global-life-sciences-virtual-conference\\\/\",\"name\":\"Verona Pharma to Present at H.C. Wainwright Global Life Sciences Virtual Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verona-pharma-to-present-at-h-c-wainwright-global-life-sciences-virtual-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verona-pharma-to-present-at-h-c-wainwright-global-life-sciences-virtual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE2MDk1MCMzOTk4NzI0IzIwODQzNjA=\",\"datePublished\":\"2021-03-01T07:03:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verona-pharma-to-present-at-h-c-wainwright-global-life-sciences-virtual-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verona-pharma-to-present-at-h-c-wainwright-global-life-sciences-virtual-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verona-pharma-to-present-at-h-c-wainwright-global-life-sciences-virtual-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE2MDk1MCMzOTk4NzI0IzIwODQzNjA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE2MDk1MCMzOTk4NzI0IzIwODQzNjA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verona-pharma-to-present-at-h-c-wainwright-global-life-sciences-virtual-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Verona Pharma to Present at H.C. Wainwright Global Life Sciences Virtual Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Verona Pharma to Present at H.C. Wainwright Global Life Sciences Virtual Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-present-at-h-c-wainwright-global-life-sciences-virtual-conference\/","og_locale":"en_US","og_type":"article","og_title":"Verona Pharma to Present at H.C. Wainwright Global Life Sciences Virtual Conference - Market Newsdesk","og_description":"LONDON and RALEIGH, N.C., March 01, 2021 (GLOBE NEWSWIRE) &#8212; Verona Pharma plc (Nasdaq: VRNA) (\u201cVerona Pharma\u201d), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Chief Executive Officer and President, will present a company overview at the H.C. Wainwright Global Life Sciences Conference. The presentation will be available on-demand starting at 7:00 AM ET on Tuesday, March 9, 2021. A webcast of the event will be available for 90 days on the Events and Presentations link on the Investors page of the Company\u2019s website,\u00a0www.veronapharma.com. \u00a0 \u00a0 Verona Pharma plc US Tel: +1-833-417-0262UK Tel: +44 (0)20 3283 4200 Victoria Stewart, Director of Communications info@veronapharma.com \u00a0 \u00a0 Argot Partners (US Investor Enquiries) Tel: +1-212-600-1902verona@argotpartners.com Kimberly Minarovich \/ Michael &hellip; Continue reading \"Verona Pharma to Present at H.C. Wainwright Global Life Sciences Virtual Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-present-at-h-c-wainwright-global-life-sciences-virtual-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-01T07:03:08+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE2MDk1MCMzOTk4NzI0IzIwODQzNjA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-present-at-h-c-wainwright-global-life-sciences-virtual-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-present-at-h-c-wainwright-global-life-sciences-virtual-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Verona Pharma to Present at H.C. Wainwright Global Life Sciences Virtual Conference","datePublished":"2021-03-01T07:03:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-present-at-h-c-wainwright-global-life-sciences-virtual-conference\/"},"wordCount":447,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-present-at-h-c-wainwright-global-life-sciences-virtual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE2MDk1MCMzOTk4NzI0IzIwODQzNjA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-present-at-h-c-wainwright-global-life-sciences-virtual-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-present-at-h-c-wainwright-global-life-sciences-virtual-conference\/","name":"Verona Pharma to Present at H.C. Wainwright Global Life Sciences Virtual Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-present-at-h-c-wainwright-global-life-sciences-virtual-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-present-at-h-c-wainwright-global-life-sciences-virtual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE2MDk1MCMzOTk4NzI0IzIwODQzNjA=","datePublished":"2021-03-01T07:03:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-present-at-h-c-wainwright-global-life-sciences-virtual-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-present-at-h-c-wainwright-global-life-sciences-virtual-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-present-at-h-c-wainwright-global-life-sciences-virtual-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE2MDk1MCMzOTk4NzI0IzIwODQzNjA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE2MDk1MCMzOTk4NzI0IzIwODQzNjA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-present-at-h-c-wainwright-global-life-sciences-virtual-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Verona Pharma to Present at H.C. Wainwright Global Life Sciences Virtual Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/446526","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=446526"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/446526\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=446526"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=446526"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=446526"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}